OTC •
Healthcare •
Biotechnology •
Quote as of 05/06/2026 11:03
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeOTC
Market Capitalization6.89 mln
Earnings Date04/23/2026
Beneish M-Score
0.49
Highly suspicious
Relative Strength
1
/ 100
Severely lagging
Debt / Equity
-0.69
Negative equity
ROE
-1,065
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Adaptimmune Therapeutics is a UK-based biopharmaceutical company focused on developing advanced cell therapies for cancer patients in the United States and United Kingdom. Its lead product, TECELRA, is an approved T-cell therapy for adults with a rare and difficult-to-treat form of soft tissue cancer called synovial sarcoma, while several other treatments are in various stages of clinical development targeting additional cancer types. The company works alongside notable partners including Galápagos, Noile-Immune Biotech, and MD Anderson Cancer Center to advance its research and expand its therapeutic reach.
